Who Generates Higher Gross Profit? Gilead Sciences, Inc. or Evotec SE

Gilead vs. Evotec: A Decade of Gross Profit Insights

__timestamp	Evotec SE	Gilead Sciences, Inc.
Wednesday, January 1, 2014	29378000	21102000000
Thursday, January 1, 2015	37987000	28633000000
Friday, January 1, 2016	58554000	26129000000
Sunday, January 1, 2017	82568000	21736000000
Monday, January 1, 2018	112016000	17274000000
Tuesday, January 1, 2019	132891000	17774000000
Wednesday, January 1, 2020	125743000	20117000000
Friday, January 1, 2021	151543000	20704000000
Saturday, January 1, 2022	174065000	21624000000
Sunday, January 1, 2023	175051000	20618000000
Monday, January 1, 2024		78200000

Infusing magic into the data realm

A Tale of Two Giants: Gilead Sciences vs. Evotec SE

In the competitive world of biotechnology, Gilead Sciences, Inc. and Evotec SE stand as titans, each with a unique story of growth and innovation. From 2014 to 2023, Gilead Sciences consistently outperformed Evotec SE in terms of gross profit, boasting figures that were nearly 200 times greater on average. In 2015, Gilead reached its peak with a gross profit of approximately $28.6 billion, while Evotec's highest was around $175 million in 2023. Despite the vast difference, Evotec has shown remarkable growth, increasing its gross profit by nearly 500% over the decade. This data not only highlights Gilead's dominance but also underscores Evotec's impressive upward trajectory. As the biotech landscape evolves, these companies continue to shape the future of healthcare with their groundbreaking research and development.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025